Cumulus Neuroscience, Muse by Interaxon Partner on Sleep EEG for Clinical Trials

Cumulus Neuroscience is collaborating with Muse by Interaxon, integrating the latter’s at-home sleep EEG into the NeuLogiq Platform, adding objective, brain-based sleep measurement to NeuLogiq’s multi-modal suite for central nervous system (CNS) clinical trials.

“Objective, reliable longitudinal data are needed to advance CNS clinical development programs, which have relied on subjective measures for too long,” Cumulus Neuroscience CEO Tina Sampath said. “Integrating Muse into the NeuLogiq Platform allows us to bring multi-modal measures of wake and sleep EEG, plus cognition, mood, and speech, out of the clinic and into study participants’ homes at scale—accelerating data collection and enabling earlier decision-making in clinical trials.”

Sleep disturbances are extremely common in neuropsychiatric and neurodegenerative disorders, often manifesting as both a symptom and a disease progression driver. Thus, sleep is increasingly treated as both a therapeutic target and a biomarker in clinical care and research. Disrupted deep sleep is linked to impaired amyloid clearance and cognitive decline—an increasingly important domain in neurodegeneration research. Yet it has been difficult to measure objectively at scale: in-lab polysomnography (PSG) is burdensome and costly, while most wearables infer sleep indirectly from movement and heart rate.

Through this collaboration, the NeuLogiq Platform sleep domain is powered by Muse—a soft, at-home EEG wearable that directly reads the brain, resolving the slow waves, spindles, and K-complexes that define each sleep stage. Muse scores full sleep architecture at 88%–96% agreement with gold-standard PSG (Lanthier et al., 2025, SLEEP Advances). The result is trial-grade sleep staging captured in the participant’s own home, with the low patient burden and repeatability required for longitudinal CNS studies—alongside NeuLogiq core measures of cognition, wake EEG, mood, and speech.

“The Muse S Athena was built to read the brain directly, at home, at scale, with best-in-class user comfort and ease-of-use at the fore,” Muse by Interaxon CEO Jean-Michel Fournier stated. “It has been proven with more than 16.8 million sessions across 500,000-plus real-world users. Bringing that to NeuLogiq means researchers can finally treat sleep as the objective, repeatable measure it should be in CNS trials, without sending participants to a lab.”

Muse by Interaxon aims to pioneer brain health through its EEG platform, built on advanced artificial intelligence (AI). Muse’s tools are underpinned by more than 200 third-party studies from institutions including the Mayo Clinic, MIT, and Harvard, and the company has decoded over 1 billion minutes of brain data—one of the world’s largest EEG collections. Muse is headquartered in Toronto.

With a mission to generate the data and insights required to accelerate diagnosis and management of central nervous system (CNS) disorders, Cumulus Neuroscience is advancing NeuLogiq, an AI-based, multi-domain digital biomarker platform to enable better, faster decision-making in neurology and neuropsychiatry clinical trials and patient care. Designed for and with 10 of the world’s leading pharma companies, the platform enables decentralized trials and is attempting to make a difference in developing therapies for Alzheimer’s disease and neuropsychiatric conditions, including depression.